Exhibit 1

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that this Statement on Schedule 13D, dated March 11, 2025 (the “Schedule 13D”), with respect to the common stock, par value $0.01 per share, of Outlook Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Joint Filing Agreement (this “Agreement”) shall be included as an Exhibit to the Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 12th day of March, 2025.

 

Dated: March 12, 2025 GMS Ventures and Investments  
     
  By: /s/ Lawrence A. Kenyon
    Name: Lawrence A. Kenyon
    Title: Attorney-in-Fact
     
  Ghiath M. Sukhtian  
     
  By: /s/ Lawrence A. Kenyon
    Name: Lawrence A. Kenyon
    Title: Attorney-in-Fact
       

 

 

   

 

Outlook Therapeutics (NASDAQ:OTLK)
Gráfica de Acción Histórica
De Feb 2025 a Mar 2025 Haga Click aquí para más Gráficas Outlook Therapeutics.
Outlook Therapeutics (NASDAQ:OTLK)
Gráfica de Acción Histórica
De Mar 2024 a Mar 2025 Haga Click aquí para más Gráficas Outlook Therapeutics.